Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORTplus in early stage follicular lymphoma
NCT05045664Phase 3Recruiting
- Sponsor
- Heidelberg University
- Start
- Jul 2022
- Primary completion
- Sep 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of obinutuzumab in follicular lymphoma (FL), sponsored by Heidelberg University. Started Jul 2022; status: recruiting.
02
Drugs
obinutuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT05045664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05045664.